Recent studies have centered on the convergence of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and DA communication. While GIP Go to store activators are commonly employed for managing type 2 diabetes mellitus, their potential consequences on motivation circuits, specifically influenced by dopamine systems, are receiving signi